[go: up one dir, main page]

NO326475B1 - Cinnolinforbindelser, anvendelse og fremstilling derav samt farmasoytisk preparat - Google Patents

Cinnolinforbindelser, anvendelse og fremstilling derav samt farmasoytisk preparat Download PDF

Info

Publication number
NO326475B1
NO326475B1 NO20030624A NO20030624A NO326475B1 NO 326475 B1 NO326475 B1 NO 326475B1 NO 20030624 A NO20030624 A NO 20030624A NO 20030624 A NO20030624 A NO 20030624A NO 326475 B1 NO326475 B1 NO 326475B1
Authority
NO
Norway
Prior art keywords
sub
sup
formula
compound
fluoro
Prior art date
Application number
NO20030624A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030624L (no
NO20030624D0 (no
Inventor
Laurent Francois Andre Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20030624D0 publication Critical patent/NO20030624D0/no
Publication of NO20030624L publication Critical patent/NO20030624L/no
Publication of NO326475B1 publication Critical patent/NO326475B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20030624A 2000-08-09 2003-02-07 Cinnolinforbindelser, anvendelse og fremstilling derav samt farmasoytisk preparat NO326475B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402255 2000-08-09
PCT/GB2001/003533 WO2002012228A1 (fr) 2000-08-09 2001-08-07 Composes de cinnoline

Publications (3)

Publication Number Publication Date
NO20030624D0 NO20030624D0 (no) 2003-02-07
NO20030624L NO20030624L (no) 2003-04-07
NO326475B1 true NO326475B1 (no) 2008-12-08

Family

ID=8173806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030624A NO326475B1 (no) 2000-08-09 2003-02-07 Cinnolinforbindelser, anvendelse og fremstilling derav samt farmasoytisk preparat

Country Status (17)

Country Link
US (1) US6887874B2 (fr)
EP (1) EP1309587B1 (fr)
JP (1) JP2004505966A (fr)
KR (1) KR100834823B1 (fr)
CN (1) CN1252065C (fr)
AT (1) ATE419245T1 (fr)
AU (2) AU2001276521B2 (fr)
BR (1) BR0113057A (fr)
CA (1) CA2415022A1 (fr)
DE (1) DE60137234D1 (fr)
ES (1) ES2317923T3 (fr)
IL (2) IL153805A0 (fr)
MX (1) MXPA02012943A (fr)
NO (1) NO326475B1 (fr)
NZ (1) NZ523388A (fr)
WO (1) WO2002012228A1 (fr)
ZA (1) ZA200300221B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
IL149034A0 (en) 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
EP1272185B1 (fr) 2000-03-06 2005-07-27 AstraZeneca AB Therapie
AU779695B2 (en) * 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
KR101093345B1 (ko) * 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DK1625121T3 (da) 2002-12-20 2010-05-10 Pfizer Prod Inc Pyrimidinderivater til behandling af abnorm cellevækst
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
WO2005111022A1 (fr) 2004-05-14 2005-11-24 Pfizer Products Inc. Derives pyrimidiques pour le traitement de la croissance de cellules anormales
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
MX2007002592A (es) * 2004-09-03 2007-10-10 Memory Pharm Corp Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
BRPI0607404A2 (pt) * 2005-03-01 2009-09-01 Wyeth Corp compostos de cinolina e seu uso como moduladores de receptor de x hepático
US20070265270A1 (en) * 2006-02-21 2007-11-15 Hitchcock Stephen A Cinnoline derivatives as phosphodiesterase 10 inhibitors
EP1991531A1 (fr) * 2006-02-28 2008-11-19 Amgen Inc. Cinnoline et derives de quinoxaline en tant qu'inhibiteurs de phosphodiesterase 10
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (fr) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Imagerie cardiaque à ciblage hsp90 et traitement associé
CN104370825B (zh) * 2014-09-29 2017-04-19 人福医药集团股份公司 作为激酶抑制剂的取代杂环化合物及其制备方法和用途
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3519816A4 (fr) 2016-09-29 2020-05-06 The Regents of the University of California Composés pour l'augmentation de la plasticité neuronale
WO2018209239A1 (fr) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Dérivés d'agélastatine puissants en tant que modulateurs de l'invasion et de la métastase du cancer
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
WO2020247054A1 (fr) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines et leurs utilisations
WO2022182415A1 (fr) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
ATE300521T1 (de) * 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
ATE480521T1 (de) 1996-10-01 2010-09-15 Kyowa Hakko Kirin Co Ltd Stickstoff enthaltende heterocyclische verbindungen
CA2291709A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa

Also Published As

Publication number Publication date
JP2004505966A (ja) 2004-02-26
US20030212055A1 (en) 2003-11-13
AU2001276521B2 (en) 2006-05-25
CN1446214A (zh) 2003-10-01
BR0113057A (pt) 2003-07-08
IL153805A0 (en) 2003-07-31
WO2002012228A1 (fr) 2002-02-14
US6887874B2 (en) 2005-05-03
IL153805A (en) 2009-05-04
MXPA02012943A (es) 2003-05-15
ZA200300221B (en) 2004-04-08
CA2415022A1 (fr) 2002-02-14
ES2317923T3 (es) 2009-05-01
CN1252065C (zh) 2006-04-19
KR100834823B1 (ko) 2008-06-09
KR20030022379A (ko) 2003-03-15
NO20030624L (no) 2003-04-07
EP1309587A1 (fr) 2003-05-14
NZ523388A (en) 2004-09-24
ATE419245T1 (de) 2009-01-15
NO20030624D0 (no) 2003-02-07
EP1309587B1 (fr) 2008-12-31
DE60137234D1 (de) 2009-02-12
AU7652101A (en) 2002-02-18

Similar Documents

Publication Publication Date Title
NO326475B1 (no) Cinnolinforbindelser, anvendelse og fremstilling derav samt farmasoytisk preparat
US7371765B2 (en) Quinoline derivatives having VEGF inhibiting activity
KR100838617B1 (ko) 혈관형성 억제제로서의 퀴나졸린 유도체
US20030207878A1 (en) Chemical compounds
NO322298B1 (no) Kinazolinderivater, anvendelse og fremgangsmåte for fremstilling derav, samt farmasøytisk preparat
NO328731B1 (no) Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk preparat.
AU2001276521A1 (en) Cinnoline compounds
NO322644B1 (no) Quinazolinderivater, anvendelse og fremstilling derav, samt farmasoytisk sammensetning.
WO2002016348A1 (fr) Derives bicycliques antiangiogeniques
AU2001276536A1 (en) Quinoline derivatives having vegf inhibiting activity
AU2001279938A1 (en) Indole, azaindole and indazole derivatives having VEGF inhibiting activity

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees